BHCM
CPRX

Boulder Hill Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Boulder Hill Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-19,700
Closed -$327K – 110
2023
Q1 		$327K Buy
+19,700
New +$325K 0.26% 78

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boulder Hill Capital Management's CPRX Position: Q2 2023 in Review

Boulder Hill Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2023, closing a stake of 19,700 shares — an estimated $327K sold.

Boulder Hill Capital Management first reported a position in CPRX in Q1 2023 and held it in 1 quarter. The position peaked at $327K in Q1 2023. 248 funds tracked by Wall St. Rank hold CPRX as of Q2 2023.

  • Boulder Hill Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 19,700 Catalyst Pharmaceutical shares in Q2 2023, an estimated $327K.
  • Boulder Hill Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 1 quarter.
  • Boulder Hill Capital Management's Catalyst Pharmaceutical position peaked at $327K in Q1 2023.
  • 248 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2023.

Based on Boulder Hill Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.